Evidence map›Paper›PMID 37042063›Full record

ArticleBiomedical chromatography : BMC2023

LC-MS/MS method for the quantitation of a dual PI3K/BRD4 inhibitor SF2523 in mouse plasma: Application to plasma protein binding and metabolism studies.

Veenu Bala, Yashpal S Chhonker, Guillermo A Morales, Krishnaiah Maddeboina, Dhananjaya Pal, Donald L Durden, Daryl J Murry

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedical chromatography : BMC, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Development and validation of a sensitive LC-MS/MS assay of GT-14, a novel GαJournal of pharmaceutical and biomedical analysis · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Veenu BalaClinical Pharmacology Laboratory, Department of Pharmacy Practice and Science, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Yashpal S ChhonkerClinical Pharmacology Laboratory, Department of Pharmacy Practice and Science, University of Nebraska Medical Center, Omaha, Nebraska, USA.ORCID https://orcid.org/0000-0001-6455-5388
Guillermo A MoralesSignalRx Pharmaceuticals, Inc., Cumming, Georgia, USA.
Krishnaiah MaddeboinaMolecular Targeted Therapeutics Laboratory, Atrium Health-Levine Cancer Institute, Charlotte, North Carolina, USA.
Dhananjaya PalMolecular Targeted Therapeutics Laboratory, Atrium Health-Levine Cancer Institute, Charlotte, North Carolina, USA.
Donald L DurdenMolecular Targeted Therapeutics Laboratory, Atrium Health-Levine Cancer Institute, Charlotte, North Carolina, USA.
Daryl J MurryClinical Pharmacology Laboratory, Department of Pharmacy Practice and Science, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Nebraska Medical Center · USAtrium Health Wake Forest Baptist · USSignalRx Pharmaceuticals (United States) · USTarget (United States) · US

Funding

UNMC/EPPLEY CANCER CENTER SUPPORT GRANTP30CA036727 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI James Eudy · 1985 to 2026
$55.0M
Tissue CoreP50CA127297 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BATRA, SURINDER K. · 2008 to 2018
$17.1M
Dual PI3K/BRD4 Inhibitory Chemotype for Maximum Inhibition of MYC and CancerR01CA215651 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI DURDEN, DONALD · 2018 to 2023
$2.3M
NCI NIH HHS P30 CA036727NCI NIH HHS P50 CA127297NCI NIH HHS R01 CA215651
6 · The paper itself

Abstract

A sensitive and selective liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) method was developed and validated for the quantitation of dual PI3K/BRD4 inhibitor SF2523 in mouse plasma. The analysis was performed on a UPLC system connected to a Shimadzu 8060 mass spectrometer by electrospray ionization in positive multiple reaction monitoring mode. Chromatographic separation was carried out on an ACE Excel C

Indexed as

Nuclear ProteinsTandem Mass SpectrometryAnimalsBlood ProteinsChromatography, High Pressure LiquidChromatography, LiquidMiceMorpholinesPhosphatidylinositol 3-KinasesProtein BindingPyransReproducibility of ResultsTranscription FactorsBlood ProteinsMorpholinesNuclear ProteinsPhosphatidylinositol 3-KinasesPyransSF2523Transcription Factorsdual PI3K/BRD4 inhibitorLC-MS/MSSF2523

Identifiers

PMID37042063
PMCPMC13492205
OpenAlexW4365136200

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.